QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 1, 2006, 26(44):11437-11441; doi:10.1523/JNEUROSCI.2436-06.2006

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Buckwalter, M. S. Articles by Wyss-Coray, T. Search for Related Content PubMed PubMed Citation Articles by Buckwalter, M. S. Articles by Wyss-Coray, T.

 Previous Article  |  Next Article 

Brief Communications
Increased T Cell Recruitment to the CNS after Amyloid _1–42 Immunization in Alzheimer's Mice Overproducing Transforming Growth Factor-1

Marion S. Buckwalter,¹ Bronwen S. Coleman,¹ Manuel Buttini,² Robin Barbour,² Dale Schenk,² Dora Games,² Peter Seubert,² and Tony Wyss-Coray^1,3

¹Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, ²Elan Pharmaceuticals, South San Francisco, California 94080, and ³Geriatric Research, Education, and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, California 94304

Correspondence should be addressed to Tony Wyss-Coray, Geriatric Research, Education, and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, CA 94304. Email: twc{at}stanford.edu

Immunotherapy targeting the amyloid (A) peptide is a novel therapy under investigation for the treatment of Alzheimer's disease (AD). A clinical trial using A_1–42 (AN1792) as the immunogen was halted as a result of development of meningoencephalitis in a small number of patients. The cytokine TGF-1 is a key modulator of immune responses that is increased in the brain in AD. We show here that local overexpression of TGF-1 in the brain increases both meningeal and parenchymal T lymphocyte number. Furthermore, TGF-1 overexpression in a mouse model for AD [amyloid precursor protein (APP) mice] leads to development of additional T cell infiltrates when mice were immunized at a young but not old age with AN1792. Notably, only mice overproducing both A (APP mice) and TGF-1 experienced a rise in T lymphocyte number after immunization. One-third of infiltrating T cells were CD4 positive. We did not observe significant differences in B lymphocyte numbers in any of the genotypes or treatment groups. These results demonstrate that TGF-1 overproduction in the brain can promote T cell infiltration, in particular after A_1–42 immunization. Likewise, levels of TGF-1 or other immune factors in brains of AD patients may influence the response to A_1–42 immunization.

Key words: A peptide; Alzheimer's disease; immunity; immunotherapy; inflammation; lymphocyte; neuropathology; T cell; vaccination

---

Received June 8, 2006; revised Aug. 28, 2006; accepted Sept. 25, 2006.

Correspondence should be addressed to Tony Wyss-Coray, Geriatric Research, Education, and Clinical Center, Veterans Administration Palo Alto Health Care System, Palo Alto, CA 94304. Email: twc{at}stanford.edu

This article has been cited by other articles:

				M. Yamamoto, T. Kiyota, S. M. Walsh, J. Liu, J. Kipnis, and T. Ikezu Cytokine-Mediated Inhibition of Fibrillar Amyloid-{beta} Peptide Degradation by Human Mononuclear Phagocytes J. Immunol., September 15, 2008; 181(6): 3877 - 3886. [Abstract] [Full Text] [PDF]

				R. Baron, A. Nemirovsky, I. Harpaz, H. Cohen, T. Owens, and A. Monsonego IFN-{gamma} enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease FASEB J, August 1, 2008; 22(8): 2843 - 2852. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help